✦ LIBER ✦

Phase II Trials of Bortezomib (PS-341, Velcade™), a Selective Proteasome Inhibitor, in Non-Hodgkin's Lymphoma

✍ Scribed by Gibson, Angelia D.; Jain, Vinay K.

Book ID: 119615119
Publisher: CIG Media Group, LP.
Year: 2003
Tongue: English
Weight: 233 KB
Volume: 4
Category: Article
ISSN: 1526-9655
DOI: 10.1016/s1526-9655(11)70013-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of the proteasome inhibit

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

✍ Li, Tianhong; Ho, Liawaty; Piperdi, Bilal; Elrafei, Tarek; Camacho, Fernando J.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 240 KB

A phase I and pharmacologic study of seq

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

✍ Cynthia Ma; Sumithra J. Mandrekar; Steven R. Alberts; Gary A. Croghan; Aminah Ja 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 310 KB

Phase II Trial of Menogaril in Non-Hodgk

Phase II Trial of Menogaril in Non-Hodgkin's Lymphomas: a Southwest Oncology Group Trial

✍ Dennis F. Moore; Thomas D. Brown; Michael LeBlanc; Steve Dahlberg; Thomas P. Mil 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 43 KB

A phase II trial of bryostatin 1 in pati

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

✍ Ranson, M; Radford, J A; Hancock, B W; Soukop, M; McGown, A T; Robbins, A; Halbe 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 76 KB

A phase II trial of promace-cytabom in p

A phase II trial of promace-cytabom in previously untreated non-hodgkin's lymphoma of intermediate- or high-grade histology

✍ G. Rossi; M. R. Mariano; G. Arcangeli; V. Bonfanti; M. A. Capucci; P. Ferremi; P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB

the aggressive combination chemotherapy programme ProMACE-CytaBOM was used at a community-based hospital as primary treatment for non-Hodgkin's lymphoma (NHL) of intermediate or high-grade histology in Ann-Arbor stages IB-IV. The 53 patients entering the study represented 90 per cent of all consecut

Phase II trial of MINE as a front-line t

Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin’s lymphomas

✍ I Çelik; A Kars; N Güler; I Barışta; G Tekuzman; Ö Özyılkan; M Hayran; D Fırat 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 35 KB